All In Biotech

Drug Trial Radar · NCT00607386

Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy

A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy

Last checked: Nov 20, 2026Latest source record: Jun 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

28

Actual

Start

Dec 31, 2007

Primary completion

Jul 8, 2011

Study completion Jul 8, 2011

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
Collaborators
Covance; PharmaNet; PRA Health Sciences
First posted
Feb 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to determine the safety of once weekly dosing of idursulfase 0.5 mg/kg administered by intravenous (IV) infusion for male Hunter syndrome patients ≤ 5 years old.

Conditions

  • Hunter Syndrome
  • Mucopolysaccharidosis II
  • MPS II

Interventions

  • IdursulfaseBiological

    Solution for intravenous infusion, 0.5 mg/kg weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety EvaluationTime frame: From the start of study treatment until 30 days after the last infusion of idursulfase, up to 53 weeks

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Hospital de Clinicas de Porto Alegre, Servico de Genetica Medica

    Porto Alegre, Rio Grande do Sul, Brazil

  • Instytut Pomnik Centrum Zdrowia Dziecka, Klinika Chorob Metaboliczynch, Endokrynologii i Diabetologii

    Warsaw, Poland

  • National Taiwan University Hospital, Dept. of Pediatrics and Medical Genetics

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.